The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in ...
Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...
First Metro Securities Brokerage Corp. (FirstMetroSec) expects a stronger year for Philippine equities in 2025, citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback